The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Identifying Patients at High Risk for Stroke Despite Anticoagulation: A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort
Open accessAbstract
Background and Purpose— The risk of stroke in patients with atrial fibrillation (AF) is not homogeneous, and various clinical risk factors have informed the development of stroke risk stratification schemes (RSS). Among anticoagulated cohorts, the emphasis should be on the identification of patients who remain at high risk for stroke despite anticoagulation. Methods— We investigated predictors of thromboembolism (TE) risk in an anticoagulated AF clinical trial cohort (n=7329 subjects) and tested the predictive value of contemporary RSS in this cohort: CHADS 2 , Framingham, NICE 2006, American College of Cardiology/American Heart Association/European Society of Cardiology 2006, the 8th American College of Chest Physicians guidelines and the CHA 2 DS 2 -VASc schemes. Results— On multivariate analysis, significant predictors of TE were stroke/TIA (hazard ratio [HR], 2.24; P <0.001), age 75 years or older (HR, 1.77; P =0.0002), coronary artery disease (HR, 1.52; P =0.0047), and smoking (HR, 2.10; P =0.0005), whereas reported alcohol use (HR, 0.70; P =0.02) was protective. Comparison of contemporary RSS demonstrated variable classification of AF patients into risk strata, although c -statistics for TE were broadly similar among the RSS tested and varied between 0.575 (NICE 2006) and 0.647 (CHA 2 DS 2 -VASc). CHA 2 DS 2 -VASc classified 94.2% as being at high risk, whereas most other RSS categorized two-thirds as being at high risk. Of the 184 TE events, 181 (98.4%) occurred in patients identified as being at high risk by the CHA 2 DS 2 -VASc schema. There was a stepwise increase in TE with increasing CHA 2 DS 2 -VASc score ( P trend <0.0001), which had the highest HR (3.75) among the tested schemes. The negative predictive value (ie, the percent categorized as “not high risk” actually being free from TE) for CHA 2 DS 2 -VASc was 99.5%. Conclusion— Coronary artery disease and smoking are additional risk factors for TE in anticoagulated AF patients, whereas alcohol use appears protective. Of the contemporary stroke RSS, the CHA 2 DS 2 -VASc scheme correctly identified the greatest proportion of AF patients at high risk, despite the similar predictive ability of most RSS evidenced by the c -statistic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationGage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Self-citationEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L. E., Asinger, R. W., Cannom, D. S., Crijns, H. J., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,348
Self-citationWang, T. J., Massaro, J. M., Levy, D., Vasan, R. S., Wolf, P. A., D'Agostino, R. B., Larson, M. G., Kannel, W. B., & Benjamin, E. J. (2003) · JAMA · doi:10.1001/jama.290.8.1049 · Cited by 780
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Fang, M. C., Go, A. S., Halperin, J. L., Lip, G. Y. H., & Manning, W. J. (2008) · Chest · doi:10.1378/chest.08-0678 · Cited by 751
Self-citationGage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Schmitt, J., Duray, G., Gersh, B. J., & Hohnloser, S. H. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn579 · Cited by 611
Independent predictors of stroke in patients with atrial fibrillation: A systematic review
The Stroke Risk in Atrial Fibrillation Working Group (2007) · Neurology · doi:10.1212/01.wnl.0000267275.68538.8d · Cited by 547
Hart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., & Asinger, R. W. (1999) · Stroke · doi:10.1161/01.str.30.6.1223 · Cited by 533
(2001) · European Heart Journal · doi:10.1053/euhj.2001.2983 · Cited by 494
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis
Heneghan, C., Alonso-Coello, P., Garcia-Alamino, J., Perera, R., Meats, E., & Glasziou, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68139-7 · Cited by 438
Hughes, M., Lip, G. Y. H., & on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-08-0508 · Cited by 371
Self-citationAntithrombotic Therapy in Atrial Fibrillation
Albers, G. W., Dalen, J. E., Laupacis, A., Manning, W. J., Petersen, P., & Singer, D. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.194s · Cited by 360
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L., Pomernacki, N. K., & Singer, D. E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.065 · Cited by 312
Goto, S., Bhatt, D. L., Röther, J., Alberts, M., Hill, M. D., Ikeda, Y., Uchiyama, S., D'Agostino, R., Ohman, E. M., Liau, C.-S., et al. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.029 · Cited by 259
Stroke Risk in Atrial Fibrillation Working Group (2008) · Stroke · doi:10.1161/strokeaha.107.501825 · Cited by 241
Atrial fibrillation and stroke prevention
Lip, G. Y., & Lim, H. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70264-8 · Cited by 239
Self-citationRietbrock, S., Heeley, E., Plumb, J., & van Staa, T. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.03.010 · Cited by 211
van Walraven, C., Hart, R. G., Wells, G. A., Petersen, P., Koudstaal, P. J., Gullov, A. L., Hellemons, B. S. P., Koefed, B. G., & Laupacis, A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.8.936 · Cited by 209
Improving Stroke Risk Stratification in Atrial Fibrillation
Lip, G. Y. H., & Halperin, J. L. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.12.013 · Cited by 185
Self-citationEffect of hypertension on anticoagulated patients with atrial fibrillation
Lip, G. Y. H., Frison, L., Grind, M., & on behalf of the SPORTIF Investigators (2007) · European Heart Journal · doi:10.1093/eurheartj/ehl504 · Cited by 168
Self-citationTransient Atrial Fibrillation Complicating Acute Inferior Myocardial Infarction
Siu, C., Jim, M., Ho, H., Miu, R. K.-M., Lee, S. W. L., Lau, C., & Tse, H. (2007) · CHEST Journal · doi:10.1378/chest.06-2733 · Cited by 128
Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation
Connolly, S. J., Eikelboom, J. W., O'Donnell, M. J., Pogue, J. M., & Yusuf, S. (2007) · Circulation · doi:10.1161/circulationaha.107.695163 · Cited by 86
Lip, G. Y. H. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0038 · Cited by 84
Self-citationFemale gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients
Lip, G. Y. H., & Lane, D. A. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-02-0106 · Cited by 79
Self-citationCan Patients at Elevated Risk of Stroke Treated With Anticoagulants Be Further Risk Stratified?
Baruch, L., Gage, B. F., Horrow, J. C., Juul‐Möller, S., Labovitz, A. J., Persson, M., & Zabalgoitia, M. (2007) · Stroke · doi:10.1161/strokeaha.106.477133 · Cited by 78
Conway, D., & Lip, G. Y. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.02.047 · Cited by 68
Self-citationCardiovascular Risk Factors and 5-Year Mortality in the Copenhagen Stroke Study
Kammersgaard, L. P., & Olsen, T. S. (2005) · Cerebrovascular Diseases · doi:10.1159/000090531 · Cited by 66
Role of Warfarin Pharmacogenetic Testing in Clinical Practice
Tan, G., Wu, E., Lam, Y., & Yan, B. P. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.8 · Cited by 66
Stroke risk in atrial fibrillation patients on warfarin
Antonucci, E., Grifoni, E., Abbate, R., Gensini, G. F., Prisco, D., & Poli, D. (2009) · Thrombosis and Haemostasis · doi:10.1160/th08-09-0592 · Cited by 46
Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
Albers, G. W. (2004) · PubMed · Cited by 34
Ischemic stroke and atrial fibrillation. A clinical study
Novello, P., Ajmar, G., Bianchini, D., Bo, G., Cammarata, S., Firpo, M. P., Parodi, C. I., Patrone, A., Pizio, N., Poeta, M. G., et al. (1993) · The Italian Journal of Neurological Sciences · doi:10.1007/bf02339217 · Cited by 9
Cited by
Developed with the special contribution of the European Heart Rhythm Association (EHRA), Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), Authors/Task Force Members, Camm, A. J., Kirchhof, P., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Van Gelder, I. C., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,864
Self-citationFriberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192
Self-citationAntithrombotic Therapy for Atrial Fibrillation
Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., et al. (2018) · Chest · doi:10.1016/j.chest.2018.07.040 · Cited by 939
Self-citationAntithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Self-citationLetham, B., Rudin, C., McCormick, T. H., & Madigan, D. (2015) · The Annals of Applied Statistics · doi:10.1214/15-aoas848 · Cited by 766
“The CHADS2 score considers only 5 factors, whereas the updated CHA2DS2-VASc score [Lip et al. (2010b)] includes three additional risk factors: vascular disease (V), age 65 to 74 years old (A) and female gender (Sc).”
BackgroundMethodInfluential
Metadata
- Authors
- Lip, G. Y. H., Frison, L., Halperin, J. L., & Lane, D. A.
- Venue
- Stroke
- Published
- 2010-12
- Volume
- 41
- Issue
- 12
- Pages
- 2731-2738
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2045093798
- Cited by
- 491
- References
- 39
- FWCI
- 25.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.